You’re reading a copy of this week’s edition of the free New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015.
Sign up to receive a copy in your inbox each Sunday morning.
As we suggested in our Sunday newsletter last weekend, “7 Key Questions for Cannabis Companies During Earnings Season“, we expect to learn a great deal from publicly traded cannabis companies this earnings season, and we were a bit surprised this week to see the update from CV Sciences depict the CBD market in such disarray. The company reported a 25% decline year-over-year in sales. This follows weak results from competitor Elixinol Global for the quarter as well.
While we have been cautious on the CBD space, as shared privately three months ago to subscribers of 420 Investor, the situation is apparently worse than we had expected. CV Sciences CEO Joe Dowling explained on the conference call that competition has intensified greatly in the natural product space, with more than 1000 new brands competing for shelf space. He pointed to low quality products with misleading marketing efforts and labeling crowding the shelves and creating customer confusion.
Readers are likely familiar with the moves made by many food, drug and mass market retailers to enter the space, but most of these stores are focused solely on topical products due to FDA regulatory concern. These products don’t have the same consumer usage intensity as the more traditional ingestible products and aren’t yet contributing significantly to top-line growth.
We continue to see the media regularly reporting the disappointment of farmers growing hemp. They are finding it difficult to find buyers and face lower prices than they expected. Litigation abounds, as well, with several cases of rampant fraud, including some companies that have allegedly sold bad seeds. One major processor has been sued by contractors for failure to make payments on construction. For much of the supply chain, reality isn’t living up to the hemp hype.
While Congress legalized hemp more than a year ago, the regulatory environment is quite uncertain. At the federal level, progress has been made, with the USDA recently establishing the U.S Domestic Hemp Production Program, but the FDA hasn’t yet finalized its regulatory oversight over CBD products. We think that once the FDA has done so, the industry is likely to move forward swiftly. The new retailers of CBD products, initially focused on just topical products, will be able to add ingestible products most likely, working with a limited number of high quality producers. Additionally, FDA accountability is likely to kill off the fly-by-night operators who have entered the space. In addition to complying with the federal regulatory landscape, CBD manufacturers will need to comply with separate state-level regulations, many of which haven’t yet been finalized. In our view, the market will improve dramatically once there is regulatory clarity.
This week will see even more cannabis companies reporting, including Charlotte’s Web, the leader in the CBD space, so we look forward to hearing how it has been faring in the “Wild West” that has developed since the Farm Act became law. Several analysts cut their estimates for the company following the CV Sciences earnings release, but none expect sales to decline, as they did for CV Sciences and Elixinol, from the $25 million reported in Q3.
As a reminder, we provide our readers with a comprehensive Cannabis Earnings Conference Call Calendar of all of the companies hosting conference calls, as well as what has become an industry benchmark for investors, the professionally managed Public Cannabis Company Revenue & Income Tracker.
Aurora Cannabis, one of the largest operators already within 25 global countries and across five continents, continues to track towards positive EBITDA. The company has shifted gears after closing 17 strategic acquisitions to a greater focus on profitability. Benefiting from economies of scale, Aurora’s vision is to define the future of cannabis globally, and it’s executing that by developing new products to market such as soft-gel capsules, sprays, hemp oil tinctures, pre-rolls and more. With the advent of new cannabis formats, the Aurora of today is quite different from the one a year or two ago. As we approach the company’s earnings report, be sure to stay tuned for Aurora’s conference call on 11/14 at 6 PM ET.
Get up to speed by visiting the Aurora Cannabis Investor Dashboard that we maintain on their behalf as a client of New Cannabis Ventures. Click the blue Follow Company button in order to stay up to date with their progress.
New Cannabis Ventures publishes curated articles as well as exclusive news. Here is some of the most interesting business content from this week:
- Bruce Linton Joins Multi-State Cannabis Operator Vireo Health as Executive Chairman
- Cannabis REIT Adjusted Funds From Operations Increases 270% in Q3
- Canopy Growth Partners with Drake to Create More Life Growth Company
- CBD Competition Leads to Decline in Q3 Sales for CV Sciences
- Columbia Care Enters Colorado with $140 Million Acquisition
- Exclusive: Global Cannabis Stock Index Declines for Seventh Consecutive Month
- GW Pharma Posts CBD Drug for Epilepsy Sales of $86 Million in Q3
- KushCo Holdings Project FY20 Revenue in Excess of $230 Million
- Exclusive: Plus Products Leverages Extreme Focus to Expand its Cannabis CPG Business
- Exclusive: This Cannabis Operator is Focused on Leading the Michigan Market Before Expanding to the East
To get real-time updates download our free mobile app for Android or Apple devices, like our Facebook page, or follow Alan on Twitter. Share and discover industry news with like-minded people on the largest cannabis investor and entrepreneur group on LinkedIn.
Get ahead of the crowd! If you are a cannabis investor and find value in our Sunday newsletters, subscribe to 420 Investor, Alan’s comprehensive stock due diligence platform since 2013. Gain immediate access to real-time and in-depth information and market intelligence about the publicly traded cannabis sector, including daily videos, weekly chats, model portfolios, a community forum and much more.
Use the suite of professionally managed NCV Cannabis Stock Indices to monitor the performance of publicly-traded cannabis companies within the day or over longer time-frames. In addition to the comprehensive Global Cannabis Stock Index, we offer a family of indices to track Canadian licensed producers as well as the American Cannabis Operator Index.
View the Public Cannabis Company Revenue & Income Tracker, which ranks the top revenue producing cannabis stocks that generate industry sales of more than US$7.5M per quarter.
Stay on top of some of the most important communications from public companies by viewing upcoming cannabis investor earnings conference calls.
Discover upcoming new listings with the curated Cannabis Stock IPOs and New Issues Tracker.
Find your place in the cannabis industry by visiting our Careers and Jobs Page and learn which companies are hiring aggressively.
Alan & Joel